Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 Long-term Extension in Narcolepsy Type 1
NCT05816382Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Apr 2023
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of oveporexton in narcolepsy type 1 (NT1), sponsored by Takeda. Primary endpoint: Treatment-emergent Adverse Events at 5 years. Started Apr 2023; status: recruiting.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT05816382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816382.